$VRTX · VERTEX PHARMACEUTICALS INC / MA
Vertex Pharmaceuticals filed its 10-Q for Q3 FY2026, reporting total revenues of $3.441B (+11.8% YoY) but net income of $653.6M, down 40% from $1.083B a year ago. Diluted EPS fell to $2.56 from $4.20. The sharp profit decline was driven by SG&A nearly doubling to $844.1M and R&D rising 35% to $1.321B, largely reflecting the Crinetics Pharmaceuticals acquisition. Operating margin compressed to 20.7% from 38.6% in the prior-year quarter.
- Q3 diluted EPS of $2.56 fell 39% YoY from $4.20, driven by a 44% surge in total costs and expenses to $2.73B.
- SG&A expenses nearly doubled to $844.1M from $445.1M, reflecting the Crinetics acquisition and launch investments.
- R&D expenses rose 35% YoY to $1.321B, while operating income dropped 40% to $712.9M from $1.186B.
- ALYFTREK revenue grew 186% YoY to $705.8M, partially offsetting TRIKAFTA's 8% decline to $2.437B.
- Total assets ballooned to $32.74B from $25.64B at year-end 2025, driven by $9.06B Crinetics acquisition adding $8.09B in intangible assets.
VRTX fell 4.05% in the regular session to $530.76 and slipped further to $528.05 in extended hours, down 0.51% after-hours. The $134.53B market cap reflects investor concern over the sharp margin compression despite 12% revenue growth.
A 40% operating-income drop at a $134B biotech giant despite double-digit revenue growth signals a costly transition period as the Crinetics deal and new launches pressure margins.
Vertex's diversification beyond CF is accelerating — CASGEVY ($99.2M, +487% YoY), JOURNAVX ($58.3M, +197%), and newly launched PALSONIFY ($10.1M) — but combined non-CF revenue remains just 5% of total product revenue, leaving the franchise heavily CF-dependent.
TRIKAFTA, the legacy CF cash cow, declined 8% YoY to $2.437B, raising questions about erosion pace as ALYFTREK ramps. The Crinetics integration added $8.09B in intangible assets and $4.5B in new debt, increasing balance-sheet risk if pipeline assets underperform.